\-\ Texto\\:\\ \ \(0\)\
\-\ normal\ \(4026\)\
\-\ patients\\ with\\ normal\\ stop\\ criteria\\ can\\ be\\ screened\\ annually\\.\ \(0\)\
\-\ using\\ tcd\\ study\\,\\ the\\ patient\\ is\\ risk\\ stratified\\ based\\ on\\ tammx\\(time\\ averaged\\ mean\\ of\\ the\\ maximum\\ velocity\\)\\ values\\.\\ \ \(0\)\
\-\ 1\\.\\ tammx\\ \\<170\\ cm\\/s\\ \\-\\ normal\\,\\ low\\ risk\ \(0\)\
\-\ 2\\.\\ tammx\\ 170\\ \\-199\\ cm\\/s\\ \\-\\ conditional\\,\\ moderate\\ risk\ \(0\)\
\-\ 3\\.\\ tammx\\ \\>200\\ cm\\/s\\ \\-\\ abnormal\\,\\ high\\ risk\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ for\\ this\\ patient\\,\\ tammx\\ values\\ for\\ the\\ intracranial\\ carotid\\ artery\\,\\ middle\\ cerebral\\,\\ and\\ anterior\\ cerebral\\ all\\ fall\\ within\\ the\\ normal\\,\\ low\\ risk\\ category\\.\ \(0\)\
\-\ this\\ patients\\ tcd\\ results\\ place\\ her\\ in\\ the\\ \\"normal\\"\\ category\\ described\\ by\\ stop\\.\ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ patient\\ is\\ a\\ 5\\ y\\/o\\ african\\ american\\ female\\ with\\ an\\ established\\ diagnosis\\ of\\ sickle\\ cell\\ anemia\\ presenting\\ for\\ a\\ annual\\ screening\\.\ \(0\)\
\-\ tcd\\ and\\ stop\\ criteria\\ remain\\ an\\ adequate\\ screening\\ tool\\.\\ \\ \\ mra\\ is\\ more\\ sensitive\\ distinguish\\ stroke\\ risk\\ among\\ patients\\ with\\ abnormal\\ tcd\\ values\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ tammx\\:\\ 0\\.28437156206343545\ \(0\)\
\-\ tcd\\:\\ 0\\.20960958047500783\ \(0\)\
\-\ cm\\/s\\:\\ 0\\.17062293723806127\ \(0\)\
\-\ risk\\:\\ 0\\.11981445086551303\ \(0\)\
\-\ stop\\:\\ 0\\.10993595241362611\ \(0\)\
\-\ 170\\:\\ 0\\.08864010677304755\ \(0\)\
\-\ values\\:\\ 0\\.08268819951670635\ \(0\)\
\-\ category\\:\\ 0\\.07221474321417158\ \(0\)\
\-\ criteria\\:\\ 0\\.06028882190419311\ \(0\)\
\-\ \\-199\\:\\ 0\\.05687431241268709\ \(0\)\
\-\ conditional\\:\\ 0\\.05687431241268709\ \(0\)\
\-\ stratified\\:\\ 0\\.05240239511875196\ \(0\)\
\-\ averaged\\:\\ 0\\.05240239511875196\ \(0\)\
\-\ screening\\:\\ 0\\.04703270230875286\ \(0\)\
\-\ screened\\:\\ 0\\.04345856053088169\ \(0\)\
\-\ normal\\:\\ 0\\.043213304987067776\ \(0\)\
\-\ patients\\:\\ 0\\.04280466966514889\ \(0\)\
\-\ annually\\:\\ 0\\.04269866997825986\ \(0\)\
\-\ tool\\:\\ 0\\.042018924715951304\ \(0\)\
\-\ velocity\\:\\ 0\\.039848136092588644\ \(0\)\
\-\ cerebral\\:\\ 0\\.03819930970018156\ \(0\)\
\-\ 200\\:\\ 0\\.037877931901935856\ \(0\)\
\-\ \\-\\:\\ 0\\.03545280887822639\ \(0\)\
\-\ mean\\:\\ 0\\.03431619911290334\ \(0\)\
\-\ established\\:\\ 0\\.0337548353903896\ \(0\)\
\-\ distinguish\\:\\ 0\\.03357806781498241\ \(0\)\
\-\ maximum\\:\\ 0\\.03276031487537503\ \(0\)\
\-\ among\\:\\ 0\\.03276031487537503\ \(0\)\
\-\ abnormal\\:\\ 0\\.03144635148793434\ \(0\)\
\-\ remain\\:\\ 0\\.030904301504718377\ \(0\)\
\-\ mra\\:\\ 0\\.030904301504718377\ \(0\)\
\-\ low\\:\\ 0\\.030660232940211606\ \(0\)\
\-\ sickle\\:\\ 0\\.030459186204802566\ \(0\)\
\-\ sensitive\\:\\ 0\\.029942781639166843\ \(0\)\
\-\ adequate\\:\\ 0\\.029557496253995088\ \(0\)\
\-\ african\\:\\ 0\\.028766513530818754\ \(0\)\
\-\ stroke\\:\\ 0\\.028766513530818754\ \(0\)\
\-\ annual\\:\\ 0\\.02763173503750479\ \(0\)\
\-\ anemia\\:\\ 0\\.02742690472579782\ \(0\)\
\-\ place\\:\\ 0\\.02678760857970601\ \(0\)\
\-\ american\\:\\ 0\\.02626184706840805\ \(0\)\
\-\ carotid\\:\\ 0\\.024722011627472014\ \(0\)\
\-\ fall\\:\\ 0\\.02425337173302058\ \(0\)\
\-\ using\\:\\ 0\\.023932728710102696\ \(0\)\
\-\ described\\:\\ 0\\.02347979800898496\ \(0\)\
\-\ intracranial\\:\\ 0\\.02330007572186905\ \(0\)\
\-\ presenting\\:\\ 0\\.02246967503678148\ \(0\)\
\-\ results\\:\\ 0\\.022255112315771913\ \(0\)\
\-\ moderate\\:\\ 0\\.021678692313605138\ \(0\)\
\-\ \\<\\:\\ 0\\.021277842112914776\ \(0\)\
\-\ based\\:\\ 0\\.021023808788819102\ \(0\)\
\-\ middle\\:\\ 0\\.02016231593317702\ \(0\)\
\-\ n\\/a\\:\\ 0\\.019969075144252172\ \(0\)\
\-\ 3\\.\\:\\ 0\\.018863704594456306\ \(0\)\
\-\ \\>\\:\\ 0\\.018317209772055254\ \(0\)\
\-\ study\\:\\ 0\\.018139557141031996\ \(0\)\
\-\ 2\\.\\:\\ 0\\.017531897689033925\ \(0\)\
\-\ 1\\.\\:\\ 0\\.017220575266436135\ \(0\)\
\-\ patient\\:\\ 0\\.016579198662897834\ \(0\)\
\-\ her\\:\\ 0\\.01657684940958023\ \(0\)\
\-\ artery\\:\\ 0\\.016416322529730316\ \(0\)\
\-\ 5\\:\\ 0\\.016130067241575247\ \(0\)\
\-\ all\\:\\ 0\\.015593054770524457\ \(0\)\
\-\ time\\:\\ 0\\.015571620820898791\ \(0\)\
\-\ y\\/o\\:\\ 0\\.015268574385933166\ \(0\)\
\-\ an\\:\\ 0\\.015247288571415869\ \(0\)\
\-\ high\\:\\ 0\\.015087393942431068\ \(0\)\
\-\ cell\\:\\ 0\\.014891875558590234\ \(0\)\
\-\ anterior\\:\\ 0\\.014198663379114435\ \(0\)\
\-\ for\\:\\ 0\\.01411177061889126\ \(0\)\
\-\ \\,\\:\\ 0\\.013972132413795477\ \(0\)\
\-\ more\\:\\ 0\\.01378823425362688\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.013549258307302046\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.013288706464401567\ \(0\)\
\-\ diagnosis\\:\\ 0\\.012659479553422063\ \(0\)\
\-\ can\\:\\ 0\\.012504660338510127\ \(0\)\
\-\ this\\:\\ 0\\.01240177049437591\ \(0\)\
\-\ female\\:\\ 0\\.011333937235147314\ \(0\)\
\-\ is\\:\\ 0\\.010883047323575335\ \(0\)\
\-\ within\\:\\ 0\\.010516976828297301\ \(0\)\
\-\ by\\:\\ 0\\.009179812278999193\ \(0\)\
\-\ be\\:\\ 0\\.008501656279638252\ \(0\)\
\-\ a\\:\\ 0\\.005117416797659371\ \(0\)\
\-\ on\\:\\ 0\\.004670264595905987\ \(0\)\
\-\ \\(\\:\\ 0\\.004660398233831358\ \(0\)\
\-\ \\)\\:\\ 0\\.004603468981376162\ \(0\)\
\-\ the\\:\\ 0\\.004459654345278252\ \(0\)\
\-\ in\\:\\ 0\\.0027186918073564834\ \(0\)\
\-\ and\\:\\ 0\\.0023226968481576574\ \(0\)\
\-\ with\\:\\ 0\\.002264596956578511\ \(0\)\
\-\ \\.\\:\\ 0\\.0016032048560091865\ \(0\)\
\-\ of\\:\\ 0\\.0015032748490063023\ \(0\)\
